Lotte Biologics (Korean: 롯데바이오로직스) is a South Korean biotechnology company headquartered in Seoul.

History

In May 2022, Lotte Group entered the bio industry in earnest by acquiring Bristol Myers Squibb's biopharmaceutical plant with a production capacity of 40,000L.[1] In June, Lotte Biologics was established as a subsidiary of Lotte Corporation.[2]

In July 2023, construction began on the first biopharmaceutical plant in Songdo, Incheon, with the goal of completion in 2025 and operation in 2027.[3] It is a project to build three factories with a production capacity of 120,000 L each by investing approximately 4.6 trillion won by 2030.[4]

References

  1. ^ "롯데, 美 BMS 바이오의약품 공장 인수… 바이오 사업 본격 진출". DongA Ilbo. 16 May 2022.
  2. ^ "롯데바이오로직스 "美공장에 ADC 적용…올해 꼭 수주할 것"". Chosun Ilbo. 17 January 2025.
  3. ^ "롯데바이오 "ADC 플랫폼 개발…뉴욕·송도 공장으로 CDMO 박차"". Yonhap News. 17 January 2025.
  4. ^ "롯데바이오, 4.6조원 투자… 송도 6만평 공장 3개 건설". Chosun Ilbo. 4 July 2017.
Allikas: https://en.wikipedia.org/wiki/Lotte_Biologics
No tags for this post.